FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 108 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Perguntas frequentes sobre COVID-19 e câncer: respostas para pacientes e sobreviventes June 23, 2020 Cancer-Free Bell Broken by Excited Patient Who Just Got Done Battling... July 17, 2019 Living With Metastatic Breast Cancer: How I Reinvented Myself October 30, 2020 20 years of Cancer Research UK: Celebrating our research nurses December 7, 2022 Load more HOT NEWS High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults... How to Stay Connected When Your Partner Has Cancer Impact of Multigene Germline Genetic Testing on Selection of Germline-Directed Therapy... Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively...
